MedTrace Logo

To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis

NCT07061925 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 169

Last updated 2025-12-24

No results posted yet for this study

Summary

A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter, Dose-finding, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of ALC-2203 in Patients with Acute Bronchitis

Conditions

  • Acute Bronchitis

Interventions

DRUG

ALC-2203-1

This group receives ALC-2203-1 and a placebo matching ALC-2203-AC, administered three times daily for 7 days.

DRUG

ALC-2203-2

This group receives ALC-2203-2 and a placebo matching ALC-2203-AC, administered three times daily for 7 days.

DRUG

ALC-2203-AC

This group receives a placebo matching ALC-2203-1 or ALC-2203-2, and ALC-2203-AC, administered three times daily for 7 days.

DRUG

Placabo

This group receives a placebo matching ALC-2203-1 or ALC-2203-2, and a placebo matching ALC-2203-AC, administered three times daily for 7 days.

Sponsors & Collaborators

  • Korea Arlico Pharm. Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-23
Primary Completion
2025-11-21
Completion
2025-11-26

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07061925 on ClinicalTrials.gov